Accendatech Co., Ltd. has recently completed the filing for IPO tutoring with the Tianjin Office of the China Securities Regulatory Commission (CSRC). China International Capital Corporation (CICC) has been appointed as the company's IPO tutoring institution.

Founded in 2008, Accendatech has a registered capital of RMB 41.47 million. The company has developed proprietary platforms for blood-brain barrier (BBB) penetration and cancer stem 

cell-targeted drug discovery.

Accendatech has no controlling shareholder. Chen Yue, Chairman and General Manager, holds a 10.0% equity stake. Board Director Wang Peng holds 10.5%. Hao Manlin is the company's 

co-founder.

According to information published on the company's website on March 31, 2026, Hao Manlin recently appeared on the Jinshang Fengyun program. During the interview, the host recalled that Chen Yue had mortgaged their only home to fund the company's early-stage research. Hao said the decision reflected the trust and commitment shared by the founding team, rather than an individual choice. She noted that the company had no clinical data at the time. The founders nevertheless decided to move forward. They believed the decision was necessary to honor the trust of investors and meet the expectations of patients. Hao said their commitment was driven by a sense of responsibility to scientific innovation, patients, and the development of innovative medicines in China.

Risk Disclosure: Investing involves risks. This article is generated by AI based on third-party information and is provided for reference only. It does not constitute investment advice.